Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman joins Natalie Stoberman from the Proactive newsroom to discuss the exclusive license of potential monoclonal antibodies from Curia Global.
Lederman says Tonix has obtained an exclusive license from Curia Global, a leading contract research, development and manufacturing organization, for the development of three humanized murine monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection.